[13C5]-Teriflunomide

[13C5]-Teriflunomide is a stable isotope-labeled version of teriflunomide, a drug used in the treatment of multiple sclerosis. It is used in research studies to track the metabolism and pharmacokinetics of the drug in the body. The stable isotope labeling of teriflunomide with carbon-13 enables researchers to track the drug’s fate in vivo using mass spectrometry and other analytical techniques. Teriflunomide is an immunomodulatory drug that works by inhibiting the activity of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the synthesis of pyrimidine nucleotides. By reducing the production of these nucleotides, teriflunomide helps to suppress the immune response that contributes to the progression of multiple sclerosis. [13C5]-Teriflunomide is chemically identical to teriflunomide, with the exception of the stable carbon-13 isotope. It has a molecular formula of C12H4D5F3N2O2 and a molecular weight of 277.22 g/mol. The drug is administered orally and is metabolized in the liver. The stable isotope label allows researchers to distinguish between the drug and its metabolites in biological samples, providing valuable information on its pharmacokinetics and metabolism in vivo. In summary, [13C5]-Teriflunomide is a stable isotope-labeled version of teriflunomide that is used in research studies to track the metabolism and pharmacokinetics of the drug in the body. Its chemical properties and mechanism of action are the same as teriflunomide, but the stable isotope labeling enables researchers to study the drug’s fate in vivo using mass spectrometry and other analytical techniques.